Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I randomized, double-blind, dose-escalation study of OATD-01

Trial Profile

A phase I randomized, double-blind, dose-escalation study of OATD-01

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs OATD-01 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Sarcoidosis
  • Focus Adverse reactions; First in man
  • Sponsors OncoArendi Therapeutics
  • Most Recent Events

    • 19 Sep 2018 Status changed to completed, according to the results presented at the 28th Annual Congress of the European Respiratory Society
    • 19 Sep 2018 Results presented at the 28th Annual Congress of the European Respiratory Society
    • 09 Oct 2017 According to an OncoArendi Therapeutics media release, the company has been granted permission from the German Federal Institute for Drugs and Medical Devices (BfArM) to begin the first-in-human clinical trial and the company will initiate this trial in this week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top